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ABSTRACT
Liquid biopsies can detect biomarkers carrying information on the development 
and progression of cancer. We demonstrated that a 24 plasma-based microRNA 
signature classifier (MSC) was capable of increasing the specificity of low dose 
computed tomography (LDCT) in a lung cancer screening trial. In the present study, 
we tested the prognostic performance of MSC, and its ability to monitor disease status 
recurrence in LDCT screening-detected lung cancers.
Between 2000 and 2010, 3411 heavy smokers enrolled in two screening programmes, 
underwent annual or biennial LDCT. During the first five years of screening, 84 lung 
cancer patients were classified according to one of the three MSC levels of risk: high, 
intermediate or low. Kaplan-Meier survival analysis was performed according to MSC and 
clinico-pathological information. Follow-up MSC analysis was performed on longitudinal 
plasma samples (n = 100) collected from 31 patients before and after surgical resection.
Five-year survival was 88.9% for low risk, 79.5% for intermediate risk and 
40.1% for high risk MSC (p = 0.001). The prognostic power of MSC persisted after 
adjusting for tumor stage (p = 0.02) and when the analysis was restricted to LDCT-
detected cases after exclusion of interval cancers (p < 0.001). The MSC risk level 
decreased after surgery in 76% of the 25 high-intermediate subjects who remained 
disease free, whereas in relapsing patients an increase of the MSC risk level was 
observed at the time of detection of second primary tumor or metastatic progression.
These results encourage exploiting the MSC test for lung cancer monitoring in 
LDCT screening for lung cancer.
INTRODUCTION
Lung cancer is the deadliest cancer worldwide, 
accounting for almost 20% of such fatalities [1, 2]. 
Lung tumors are typically asymptomatic in their early 
stages and are often diagnosed too late, thus failing in 
successful treatment. Considering that 5-year survival 
for stage IA patients is over 70% it appears clear how 
advances in early detection are crucial to enable timely 
curative surgery [3, 4].
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In the last two decades, several lung cancer screening 
programs based on low-dose computed tomography (LDCT) 
were launched worldwide. A significant reduction in lung 
cancer mortality was reported among the subjects enrolled 
in the LDCT arm of the National Lung Screening Trial 
(NLST) when compared to the chest X-ray arm [5], along 
with a false positive rate of 96.4% and an overdiagnosis 
global rate of 18.5%, reaching 78.9% for indolent cancers 
in the LDCT arm [6]. While waiting for the results of the 
Dutch-Belgian Randomized Lung Cancer Screening trial 
(NELSON) trial [7], other smaller randomized LDCT 
studies did not show similar reduction in mortality [8–10], 
raising further concern on the generalizability of the NLST 
results to different screening settings [11].
Several studies are currently investigating the 
value of complementary non-invasive biomarkers for risk 
stratification, to improve cost-benefit ratio and possibly 
mortality reduction in LDCT screening. MicroRNAs 
(miRNAs) are small non-coding RNAs that specifically 
repress translation of target mRNAs and whose altered 
expression is associated with a variety of physiological 
processes and diseases including cancer [12]. MiRNAs 
are released into the bloodstream by the tumor and its 
microenvironment and are stable, given that they mostly 
circulate within exosomes or bound to specific proteins (i.e. 
Ago2) which protect them from RNase degradation [13–16]. 
Their reliability to detect cancer through a minimally invasive 
liquid biopsy makes miRNAs highly promising biomarkers to 
be employed in clinical settings [17]. We recently described, 
in a LDCT-based lung cancer screening trial, the diagnostic 
and prognostic performance characteristics of a circulating 
miRNA signature risk classifier (MSC test) for the early 
detection of lung cancer and its ability to reduce the false 
positive rate of LDCT from 19.7% to 3.7% [18].
In the present study, we evaluated the prognostic 
performance of the MSC test, as well as its ability to 
monitor the disease status and recurrence in lung cancer 
patients identified in LDCT screening programs with 
a total follow up of 33402 person-years. The MSC test 
was employed to analyze longitudinally-collected plasma 
samples obtained from patients before and after surgical 
resection of primary lung tumors.
RESULTS
Characteristics of subjects
The characteristics of the 3411 subjects enrolled in 
the pilot study (30.3%) and in the MILD screening trial with 
annual (34.9%) or biennial LDCT (34.8%) are reported in 
Table 1 according to age, sex, and tobacco habits. Mean age, 
gender, and smoking pack years were similar across the two 
studies considered, while the percentage of current smokers 
enrolled was higher in the pilot study (87% vs. 69%). 
A total of 111 subjects (3.3%) out of 33402 person-years 
follow-up, developed lung cancer within the first 5 years of 
screening, with 25 months median time from enrollment to 
diagnosis. For 84 (75.7%) of them, plasma samples were 
available to perform the MSC test.
Ninety-nine (89.2%) lung cancers were detected as 
part of scheduled LDCT screening, 65 (58.6%) in stage I 
and 46 (41.4%) in stages II–IV. Twelve (10.8%) subjects 
developed lung cancer in the interval between two rounds 
of screening, all in stages II–IV indicating the significantly 
more advanced stage of non-LDCT-detected lung tumors 
(p < 0.001). Similar distributions were observed in the 
subset of 84 patients suitable for MSC analysis (Table 2).
MSC results according to clinico-pathological 
information
The associations between MSC at diagnosis and 
clinico-pathological features are summarized in Table 2. 
The high risk (n = 39), intermediate (n = 36) or low 
(n = 9) risk MSC groups were similarly distributed across 
the LDCT-detected tumors and the interval cancers (p = 
1.0). A significant association between MSC and tumor 
stage was observed, since the low and the intermediate 
MSC risk groups were mostly composed by stage I tumors 
(55.6% and 75.0%, respectively) and the high risk group 
included 43.6% stage I tumors (p = 0.04).
Survival according to clinico-pathological 
characteristics
The 5-year overall survival of the 84 patients was 
61.6% (95% CI: 50.0%–71.3%, Figure 1A). Pathologic 
tumor stage was the most robust prognostic factor, with a 
93.4% 5-year overall survival for stage I (median survival 
nc) and 8.2% for stage II–IV (median survival 1.5 yrs, p < 
0.001, Figure 1B). While the 5-year overall survival was 
68.2% (95% CI: 56.0%–77.6%) in LDCT-detected cases, 
all the subjects with the interval cancers survived less than 
2 years (median survival 0.6 years, p < 0.001, Figure 1C).
Integration of MSC results with 
clinico-pathological characteristics
Five-year survival was respectively 88.9% (95% CI: 
43.3%–98.4%) for low risk MSC, 79.5% (95% CI: 61.6%–
89.7%) for intermediate risk MSC and 40.1% (95% CI: 
24.7%–55.1%) for high risk MSC (p = 0.001, Figure 2A). 
In the low risk group only one death was observed in a 
patient who developed a stage IV interval cancer. After 
adjusting for stage, the impact of MSC on survival was 
still significant (p = 0.02).
The prognostic value of MSC was maintained when 
the analysis was restricted to LDCT-detected cases with 
5-years survival 100% for low risk MSC, 86.9% (95% 
CI: 68.8%–94.9%) for intermediate risk MSC and 44.7% 
(95% CI: 27.8%–60.3%) for high risk MSC (p < 0.001, 
Figure 2B).
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Monitoring lung cancer patients using MSC
To evaluate MSC modulation during follow-up, 
longitudinal plasma samples (n = 100) before and after 
curative surgery were analyzed in a subset of 31 out of 
44 (70.5%) alive patients (28 disease-free and 3 relapsing 
patients) of the MILD trial. At time of diagnosis, 11 of the 
28 (39%) patients who remained disease-free after surgery 
were high, 14 (50%) intermediate and 3 (11%) low risk 
according to the MSC test (Figure 3). The MSC test was 
already positive in 14 participants with a plasma sample 
available before diagnosis (median time = 1.1 years, 
IQR = 1.0). Considering the 25 high and intermediate 
risk subjects at diagnosis, reduction of MSC risk profile 
from high to low (n = 5), high to intermediate (n = 3) and 
intermediate to low (n = 11) was observed in 19 (76%) 
first post-surgery plasma sample (median time = 1.6 
years, IQR = 1.4, p = 0.01). Of these 25 subjects none 
had an increase in the MSC risk profile from diagnosis 
to first post-surgery plasma sample. Of the 17 patients 
with a second post-operative plasma sample available 
(median time = 4.0 years, IQR = 3.3), a further reduction 
Table 2: Distribution of lung cancer patients according to MSC at time of diagnosis
All patients 
(N = 111)
MSC (N = 84)
P for 
comparisonLow 
(N = 9)
Intermediate 
(N = 36)
High 
(N = 39)
LDCT-detected
     Yes 99 (89.2%) 8 (9.5%) 33 (39.3%) 35 (41.7%) 1.0
     No 12 (10.8%) 1 (1.2%) 3 (3.6%) 4 (4.7%)
Stage
     I 65 (58.6%) 5 (5.9%) 27 (32.1%) 17 (20.2%) 0.04
     II–IV 46 (41.4%) 4 (4.8%) 9 (10.7%) 22 (26.3%)
MSC: miRNA signature classifier; LDCT: low-dose computed tomography
Table 1: Baseline characteristics of lung cancer screening participants and information on lung 
cancer patients by study arm
Pilot studyAnnual CT MILD Annual CT MILD Biennial CT
Starting date 2000 2005 2005
No. participants 1035 1190 1186
Total Follow up (person-year) 13406 10016 9980
Age, mean ± SD 58.5 ± 5.6 58.1 ± 6.0 58.1 ± 5.8
Male, N (%) 740 (71%) 814 (68%) 812 (68%)
Current smokers, N (%) 901 (87%) 820 (69%) 809 (68%)
Pack-years of 
cigarettes,Median (IQR) 40 (28) 39 (20) 39 (19)
Patients at 5 years, N 41 42 28
Histology: adenocarcinoma 29 24 19
other types 12 18 9
Patients with plasma 
MSC, N 18 40 26
MILD: Multicentric Italian Lung Detection trial; SD: standard deviation; IQR: interquartile range; MSC: miRNA signature 
classifier.
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Figure 1: Kaplan Meier curves for overall lung cancer patients with a miRNA signature classifier (MSC) (N = 84) 
A. also in strata of clinical characteristics: stage I and other stages together B. low-dose computed tomography 
(LDCT)-detected and non LDCT-detected C. P for log rank test.
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of risk profile was observed, being 76% low and 24% 
intermediate risk, while none remained high risk.
Of 3 patients with recurrent disease, a stage I 
adenocarcinoma (ADC) with high risk returned to low 
risk after curative surgery, but raised to intermediate risk 
when developed a second primary lung cancer 3 years later 
(Figure 4A). A second patient with a stage I ADC and an 
intermediate risk MSC decreased to low risk after surgery, 
while the MSC test on a plasma sample collected 3 years 
later, after radiotherapy to treat a lung metastasis to the 
brain, revealed an intermediate risk (Figure 4B). A third 
patient with a stage I ADC decreased from intermediate to 
low risk 10 months after surgery, then raised to intermediate 
25 months later and finally to high risk 10 months before a 
lung nodule resection which at histopathological analysis 
resulted a metastatic site of a primitive breast cancer 
occurred 4 years before (Figure 4C).
DISCUSSION
The present study provides further validation of the 
MSC test [18], a plasma-based miRNA test, and suggests 
its clinical utility as both prognostic and monitoring 
tool, alone as well as in combination with other clinico-
pathological parameters. Analysis on 84 lung cancer 
patients identified in large LDCT screening cohorts (33402 
person-years) revealed a very poor outcome of stage II–IV 
lung cancer cases and of interval tumors occurred among 
two rounds of screening.
The MSC analysis stratified the patients according 
to their survival, even after adjusting for tumor stage, 
and was able to refine prognosis within specific clinico-
pathological groups. In particular, 20 out of 24 (83%) 
LDCT-detected patients who died were high risk according 
to the MSC test. Moreover, 63% of stage II–IV patients, 
as well as all 3 stage I patients who died at five years, 
were high risk highlighting the additional prognostic 
value of the MSC. On the other hand, patients with low 
or intermediate MSC risk were mostly (71%) stage I with 
a better and longer survival. If confirmed in larger series, 
the MSC test might be utilized for selecting patients with 
high risk profile who could benefit from adjuvant therapies 
irrespective of low stage disease.
Noteworthy, only 9 (11%) of the 84 patients were 
low risk MSC supporting the sensitivity of the MSC 
testing and the only patient who died was an interval 
cancer at stage IV that was also missed by LDCT imaging. 
On the other hand, MSC identified 7 of the 8 patients with 
interval cancer and a plasma sample available and 31 of 
the 35 (89%) stage II–IV patients. Combination of MSC 
and LDCT seems therefore effective to improve sensitivity 
of lung cancer screening.
Liquid biopsies-based biomarkers could be used to 
assess non-invasively the level of the individual risk. Our 
previous finding that MSC test identified intermediate or 
high risk subjects before lung cancer detection by LDCT 
[13, 18] supports our conclusion that the 24 miRNAs 
composing the MSC could be likely released from the 
damaged/diseased lung microenvironment, in particular 
from epithelial and/or stromal components which are 
strongly affected by smoking carcinogen exposure, 
signaling tumor onset and reflecting the tumor biological 
aggressiveness [22]. Indeed, several miRNA composing 
MSC control biological pathways highly relevant in lung 
cancer onset. mir-17, 19b, 92a, 106a are key oncogenic 
components of the oncomir clusters mir-17~92 and mir-
106a-363, whose deregulation have been widely reported 
in numerous solid tumors, including lung [23] and also 
Figure 2: Kaplan Meier curves for lung cancer patients according to integration of miRNA signature classifier (MSC) 
analysis (N = 84) A. and clinical and pathological information: MSC analysis among low-dose computed tomography 
(LDCT)-detected only (N = 76) B. P for log rank test for trend. H: high; I: intermediate; L: low.
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in regulation of response to microenvironmental toll-like 
receptor triggering [24]. Mir-197 and mir-660 target NOXA 
and MDM2 p53- related genes, respectively, and their 
replacement has been shown to achieve therapeutic effect 
in p53-wild type cancer [25, 26]. Mir-221 and mir-486-5p 
block PTEN expression leading to activation of the PTEN/
AKT survival pathway [27]. Interestingly, other miRNAs of 
the MSC signature behave as general sensors of metabolic 
and stress related pathways such a mir-451 [28], a sensor 
of glucose levels which regulates LKB1/AMPK signaling 
and allows adaptation to metabolic stress and mir-486-5p, 
a cardiac/skeletal muscle enriched miRNA whose reduced 
expression in plasma may reflect cancer-induced skeletal 
muscle dysfunction and cachexia [29].
We present here the first evidence that the MSC test 
can be successfully employed to monitor the disease status 
at follow-up in LDCT screening detected lung cancer 
patients. The significant reduction of the MSC risk result 
after curative surgery observed in subjects who remained 
disease-free, together with the observation that in the three 
relapsing patients the MSC test returned to intermediate 
or high risk at the time of second primary or metastatic 
progression, were indications of the biological specificity 
of MSC test to lung cancer.
Conversely, a subset of subjects (24%) retained an 
elevated MSC profile even after cancer removal which 
could reflect the persistence a host/microenvironment–
related risk profile. In this regard, the MSC could improve 
screening performance with LDCT by reducing further 
follow-up exams in low risk subjects while focusing 
efforts and resources towards subjects with an elevated 
risk after MSC analysis, who are potentially more likely 
to relapse.
In conclusion, this study shows that the MSC results 
obtained from lung cancer patients detected in screening 
programs with extended follow-up may be sensitive and 
accurate to improve individual risk assessment and may 
be adequate for clinical decision-making.
Figure 3: miRNA signature classifier (MSC) of 28 patients pre-diagnosis (Pre, median time from diagnosis = 1.1 years, 
IQR = 1.0), at diagnosis and remaining disease-free after curative surgery, at two post-operative time points: PD1 
(median time from diagnosis = 1.6 years, IQR = 1.4) and PD2 (median time from diagnosis = 4.0 years, IQR = 3.3). 
H: high; I: intermediate; L: low.
Oncotarget32874www.impactjournals.com/oncotarget
PATIENTS AND METHODS
Study population
In 2000 a five-year prospective pilot trial offering 
yearly LDCT to 1035 current or former heavy smokers 
volunteers with a smoking history of at least 20 pack-years, 
50 years of age or older, was launched in Milan [19]. In 
2005, the Multicentric Italian Lung Detection (MILD) trial 
was initiated and over the following 5 years it enrolled 4099 
heavy-smoker volunteers with the same characteristics of 
the previous trial. Volunteers were randomized to a control 
arm and an early detection arm, the subjects of the latter 
group further randomized to receive annual or biennial 
Figure 4: miRNA signature classifier risk profile (MSC) of 3 lung cancer patients with recurrent disease. D1: miRNA 
signature at diagnosis; D2: time at second diagnosis with miRNA signature (if available); PD1, PD2, PD3: miRNA signature at first, second 
and third post-operative plasma sample, respectively. H: high; I: intermediate; L: low.
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LDCT [8]. Details of these screening programs were 
described elsewhere [8, 19].
Overall, between 2000 and 2010, a total of 3411 
subjects underwent annual (2225) or biennial (1186) 
LDCT and 111 subjects developed lung cancer during the 
first five years of screening.
Plasma samples of 84 subjects with lung cancer 
collected at the time of disease detection were available 
to perform the MSC test. For 31 patients who underwent 
curative resection of their primary lung cancer multiple 
(n = 100) plasma samples were also suitable for MSC analysis.
All participants were followed up until January 
2015. Median follow-up of the alive patients was 5.9 
years (IQR = 3.8). The actuarial five-year overall survival 
according to clinical and pathological characteristics was 
calculated for the subset of 84 patients suitable for plasma 
MSC analysis, according to three different risk groups 
(high, intermediate or low) [18].
MicroRNA profiling
Total RNA was extracted from 200 μl of plasma 
using the mirVana PARIS Kit (Life-Technologies) and 
eluted in 50 μl of buffer. MicroRNA expression was 
determined in 3 μl of eluted RNA using the Multiplex 
Pools Protocol on custom-made microfluidics card (Life-
Technologies) as previously described [18, 20].
Patients were classified as low, intermediate or 
high risk MSC based on the algorithm generated from 
the combination of four different signatures as previously 
described [18] and summarized in Supplementary 
Table S1. Briefly, low risk MSC included patients negative 
for all signatures, whereas positive patients were classified 
as intermediate risk MSC when positive for risk of disease 
(RD) and/or presence of disease (PD) only, and as high 
risk MSC when at least one of the two signatures of 
aggressive disease (RAD, PAD) was positive.
Statistical analysis
The continuous variables were given as mean values 
± standard deviation (SD) and median with IQR. The 
categorical variables were analyzed using contingency 
table analysis and the Chi-squared test with Yates 
correction or Fisher’s exact test, as appropriate. Survival 
curves were estimated using the Kaplan-Meier method and 
were compared by the log-rank test [21].
Among patients with a MSC risk profile at diagnosis 
and at first post-operative plasma sample, we tested the 
hypothesis that the reduction of the intermediate and 
high MSC risk profile (defined as a reduction level of 
at least one step) was statistically different from 50%. 
All tests were two-sided and p-values < 0.05 were 
considered statistically significant. Statistical analyses 
were performed using SAS 9.2 statistical software (SAS 
Institute, Cary, NC) and STATA statistical software 
(version 11; StataCorp, College Station, TX, USA).
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